Pharma News
26 Oct 2025 to 01 Nov 2025
Nov 1, 2025
How Royalty Pharma Generates Revenue While Avoiding Major Biotech Risks - TradingView
Royalty Pharma plc (RPRX) has achieved over 42% stock appreciation this year by operating as a strategic financier in biotechnology. The company raised $2 billion for growth and acquired a royalty interest in Amgen's cancer therapy IMDELLTRA. With a diversified portfolio of over 35 therapies, Royalty Pharma offers a lower-risk investment model, despite ongoing disputes with Vertex Pharmaceuticals (VRTX).
Nov 1, 2025
Recent court decisions underscore the potential dangers for Japanese pharmaceutical companies when resolving legal disputes.
The Second Circuit Court of Appeals upheld the dismissal of antitrust claims in Watson Labs. v. Forest Labs., where Forest Laboratories settled patent litigation over Bystolic with generic manufacturers. Meanwhile, CVS Pharmacy accused Takeda Pharmaceutical and TWi Pharmaceuticals of an illegal reverse payment agreement regarding Dexilant. The ruling emphasizes scrutiny on settlements that provide value to generics.
Nov 1, 2025
Potential Reactions from Investors Following Jazz Pharmaceuticals' Global Settlement on LUMRYZ
Avadel Pharmaceuticals and Jazz Pharmaceuticals reached a global settlement in October 2025, resolving litigation over LUMRYZ and sodium oxybate patents. The agreement clarifies intellectual property and establishes future royalty streams, impacting Jazz's revenue outlook in sleep disorders. Jazz forecasts $5 billion in revenue by 2028, amid challenges from patent expirations and competition.
Nov 1, 2025
Reasons Behind AbbVie's Stock Decline on Friday - The Globe and Mail
AbbVie (NYSE: ABBV) reported a strong third quarter with nearly $15.78 billion in revenue, driven by blockbuster drugs like Skyrizi and Rinvoq. However, its raised profitability guidance fell short of analyst expectations, leading to a 4% drop in stock price. CEO Robert Michael highlighted progress in their pipeline, despite the disappointing outlook for 2025.
Nov 1, 2025
The 20 Leading Medications Approaching Patent Expiration Between 2026 and 2029
The biopharma industry faces a significant "patent cliff" as key patents on blockbuster drugs worth approximately $230 billion in annual sales are set to expire by 2030. Major acquisitions include Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, Merck's $10 billion purchase of Verona Pharma, and Sanofi's $9.5 billion acquisition of Blueprint Medicines.
Nov 1, 2025
Pfizer Shares Rise Following Trump's Agreement on Drug Pricing and $7 Billion Investment in Obesity Treatment - ts2.tech
Pfizer's stock (NYSE: PFE) has fluctuated around $24 after a recent surge due to a deal with the Trump administration to cut Medicaid drug prices. The company is also acquiring Metsera Inc. for up to $7.3 billion to enter the obesity drug market. Analysts remain cautiously optimistic, with a consensus rating of Hold and potential for significant upside if new products succeed.
Nov 1, 2025
DCGI empowers Joint Drug Controllers to expedite approval processes.
The Central Drugs Standard Control Organisation (CDSCO) has delegated licensing authority powers to Joint Drug Controllers to expedite approvals for import licenses and decisions on serious adverse events (SAE). This move aims to enhance the efficiency of the drug approval process in India.
Nov 1, 2025
Eli Lilly's Major Medications Drive Unprecedented Quarterly Results - Ad-hoc-news.de
Eli Lilly reported record third-quarter earnings, with revenue soaring 54% to $17.6 billion, driven by its diabetes drug Mounjaro and obesity medication Zepbound. Mounjaro generated $6.52 billion, while Zepbound's sales rose 184% to $3.57 billion. The company is investing $1.2 billion in manufacturing and anticipates continued growth, raising its full-year revenue guidance to $63.0-$63.5 billion.
Nov 1, 2025
Jammu District Magistrate takes action to prevent the abuse of courier services in drug trafficking.
Jammu authorities have implemented strict regulations to prevent the misuse of courier services for drug trafficking. The order targets the transport of narcotic drugs and psychotropic substances (NDPS) through logistics networks, aiming to enhance control and enforcement in the district.
Oct 31, 2025
Eli Lilly expresses worries to the Government regarding suggested modifications to EU legislation | Irish Independent
Eli Lilly has expressed concerns to the Department of Enterprise regarding proposed changes to patent law in Europe, arguing they are misaligned with global standards. The company, known for its weight-loss drug Zepbound and diabetes treatment Mounjaro, emphasizes the need for a strong intellectual property framework to foster innovation and investment in new medicines.
Oct 31, 2025
NCLAT rules that CCI is unable to investigate anti-competitive behavior related to patented medications - Bar and Bench
The Competition Commission of India (CCI) dismissed allegations against Vifor, the patent holder for Ferric Carboxymaltose (FCM), regarding anti-competitive practices. The claims suggested Vifor limited supply and inflated prices for the iron-deficiency anaemia treatment. However, the CCI found no merit, noting Vifor's licensing agreements with Emcure and Lupin were reasonable and did not restrict competition.
Oct 31, 2025
Two Additional Infant Fatalities Linked to Suspected Contaminated Cough Syrup, Reports DrugsControl Media Services
Two more infants have died in Madhya Pradesh, India, allegedly due to contaminated cough syrups, raising concerns over safety. This incident follows a series of similar tragedies, highlighting the urgent need for regulatory scrutiny in the pharmaceutical sector.
Oct 31, 2025
Research Analyzes Finerenone Versus Spironolactone for Managing Chronic Kidney Disease in Type 2 Diabetes
A recent study published in *Nature Communications* compared the efficacy and safety of finerenone and spironolactone in treating chronic kidney disease (CKD) in type 2 diabetes patients. Utilizing a target trial emulation approach, the research aims to provide insights into the relative effectiveness of these mineralocorticoid receptor antagonists, enhancing treatment options for this patient population.
Oct 31, 2025
Onconic Therapeutics receives national authorization for Ja Q Bo oral disintegrating tablet aimed at treating GERD.
Onconic Therapeutics has received marketing approval for a new orally disintegrating tablet formulation of its gastroesophageal reflux disease treatment, Ja Q Bo (ingredient: zastaprazan). This formulation, designed for older patients, dissolves quickly without water and replaces the typical mint flavor with orange. Ja Q Bo is now available in 26 countries, with ongoing expansion efforts in the global P-CAB market.
Oct 31, 2025
Mounjaro and Zepbound Exceed Sales of Top Cancer Medications - Asia Economy
Eli Lilly's products, Mounjaro and Zepbound, have surpassed Merck's Keytruda, achieving $10.09 billion in sales in Q3 2023. Mounjaro generated $6.51 billion, while Zepbound contributed $3.58 billion. Merck's Keytruda recorded $8.1 billion. Eli Lilly's overall sales rose 54% to $17.6 billion, prompting an increase in annual sales guidance.
Oct 31, 2025
Boost for Indian pharmaceutical companies as US FDA relaxes regulations on biosimilar approvals.
The US FDA has proposed reforms to accelerate biosimilar development, easing requirements for Indian drugmakers like Sun Pharma, Lupin, and Aurobindo. The changes aim to make biologics more affordable, potentially enhancing access to treatments like Humira and Keytruda. With over 55 blockbuster biologics losing patent protection soon, Indian firms are poised for significant growth in the biosimilars market.
Oct 31, 2025
What Can Imitate Nature? Support Major Pharmaceuticals? And Unite Congress?
USC hosted its second Quantum Technologies Forum, highlighting advancements in quantum computing, which could revolutionize drug discovery. The event featured experts from academia, industry, and government, including representatives from AstraZeneca and D-WAVE Systems. With significant funding and initiatives, California aims to develop a statewide quantum strategy by 2026, positioning itself as a leader in this emerging field.
Oct 30, 2025
Collector Pratibha Pal Directs Closure of More Than Twelve Pharmacies in Counterfeit Medication Case
Rewa Collector Pratibha Pal has ordered the sealing of over a dozen medical stores in response to a crackdown on the sale of counterfeit and expired medicines. This action follows a series of aggressive raids aimed at addressing the alarming issue in the district.
Oct 30, 2025
Novo Nordisk competes with Pfizer in the acquisition of US biotech firm Metsera.
Novo Nordisk has launched a rival bid of up to $8.5 billion for U.S. obesity biotech firm Metsera, surpassing Pfizer's $7.3 billion offer. Metsera deemed Novo's bid "superior," prompting Pfizer to express concerns over competition. This move aligns with Novo's strategy to enhance its obesity and diabetes pipeline amid growing market competition, particularly against Eli Lilly.
Oct 30, 2025
FDA simplifies the approval process for biosimilars, reduces development expenses, and supports South Korean companies.
The FDA has proposed new guidelines to streamline the approval process for biosimilars, aiming to reduce development costs and market entry barriers. The changes, part of President Trump's drug price reduction policy, will allow for fewer clinical trials and simplify procedures. This is expected to enhance competition and lower drug prices, benefiting companies like Samsung Bioepis and Celltrion.
Oct 30, 2025
BioNxt Secures 'Readiness to Grant' from EAPO for Patent Across Eight States | BNXTF Stock Update
BioNxt Solutions Inc. has received a "Readiness to Grant" patent notification from the Eurasian Patent Organization for its sublingual delivery system of anticancer drugs, including its lead product BNT23001, a formulation of Cladribine for multiple sclerosis. The patent will cover eight Eurasian countries, enhancing BioNxt's commercialization strategy as it advances clinical programs and international patent protections.
Oct 30, 2025
Global Market for Large Molecule Drug Substance CDMO: Size, Share, Trends, and Growth Insights
The large molecule drug substance CDMO market is expected to grow at a CAGR of 9%, driven by rising demand for biologics and biosimilars, advancements in bioprocessing, and increased FDA and EMA approvals. Key players include Eurofins Scientific, WuXi Biologics, and Boehringer Ingelheim. The shift towards biologics is reshaping the pharmaceutical landscape, enhancing treatment options for chronic diseases.
Oct 30, 2025
Merck's third-quarter earnings surpass forecasts due to strong sales of its new vaccine - The Edge Malaysia
Merck & Co reported strong third-quarter sales, driven by its pneumonia vaccine Capvaxive, which generated $244 million, surpassing expectations. Adjusted earnings reached $2.58 per share. However, sales of Keytruda and Winrevair fell short, as Merck prepares for upcoming patent expirations. The company also faces challenges with Gardasil sales in China and has paused shipments.
Oct 30, 2025
FDA Fast-Tracks Biosimilar Approvals: Simplified Process Aims to Lower Costs for Biotech Medications
The FDA has announced a streamlined approval process for biosimilars, aiming to reduce costs and timelines for biotech medications. This initiative targets expensive biologic drugs used in treating conditions like cancer and rheumatoid arthritis, promising significant savings for patients.
Oct 30, 2025
ANDA Litigation Settlements for Q3 2025 | Robins Kaplan LLP - JDSupra
Numerous pharmaceutical patent cases have been resolved, including Merck's injunction against Aurobindo for Janumet XR® (metformin HCl/sitagliptin phosphate), and Biogen's dismissal against Zydus for Vumerity®. Other notable cases involve AbbVie and Aurobindo regarding Rinvoq® and Gilead's injunction against Lupin for Biktarvy®. Most parties will bear their own costs, with various claims dismissed without prejudice.
Oct 30, 2025
FDA Aims to Simplify Processes for Biosimilars - IPWatchdog.com
The FDA has announced draft guidance aimed at easing the development of biosimilars to lower drug prices. The guidance suggests that comparative analytical assessments may suffice for demonstrating biosimilarity, potentially reducing unnecessary clinical testing. This move is expected to expedite access to affordable treatments for chronic diseases, with biosimilars having already saved $56 billion in healthcare costs since 2015.
Oct 30, 2025
Feinsinger's column: The pharmaceutical industry requires reform | PostIndependent.com
The article critiques the pharmaceutical industry's shift from altruism to profit-driven motives, highlighting issues like excessive lobbying, high drug prices, and the prevalence of "me too" drugs. It emphasizes the need for reforms, advocating for access to medications based on medical need, affordability, and prioritizing public health over patents. Dr. Greg Feinsinger's insights and the PNHP's principles for reform are also discussed.
Oct 30, 2025
Eli Lilly Raises Projections for 2025 Earnings and Revenue Amidst GLP-1 Drug Developments | IndexBox
Eli Lilly has raised its full-year profit and revenue forecast, anticipating strong demand for its GLP-1 drugs. The company now expects earnings of $23.00 to $23.70 per share, up from a previous estimate of $21.75 to $23.00. Analysts had projected a profit of $22.18 per share for 2025, according to Reuters.
Oct 30, 2025
MSD surpasses revenue forecasts as it shifts focus to new medications - Irish Examiner
Merck & Co (MSD) exceeded third-quarter sales expectations, driven by strong pneumonia vaccine results, while preparing for the patent loss of its key drug, Keytruda, expected in 2028. The company cut R&D spending by over $1.6bn and trimmed its 2025 sales guidance by $300m. Merck also received US approval for a new formulation of Keytruda, called Keytruda Qlex.
Oct 30, 2025
UPDATE 2 - Merck reports increased sales in the third quarter, driven by Keytruda's growth despite a decline in Gardasil revenue.
Merck & Co reported a third-quarter revenue of $17.28 billion, driven by a 10% increase in sales of its cancer drug Keytruda, totaling $8.1 billion. However, shares fell 3% as the company narrowed its full-year revenue guidance to $64.5-$65.0 billion. Sales of the HPV vaccine Gardasil declined, while lung disease drug Winrevair saw a 141% increase.
Oct 30, 2025
Novo Nordisk responds to competition with a $9 billion offer for a company specializing in obesity treatments.
Generics of Semaglutide are expected to enter the Canadian market by 2026, following Novo Nordisk's inability to uphold a crucial patent. This development raises questions about whether it was a strategic decision or an oversight, particularly in a country recognized for its stringent drug price regulations.
Oct 30, 2025
Eli Lilly Announces Impressive Third Quarter Performance, Increases 2025 Projections Due to Mounjaro and Zepbound
Eli Lilly (LLY) reported a remarkable third-quarter performance, exceeding expectations with $17.6 billion in revenue, driven by its diabetes drug Mounjaro, which generated $6.52 billion, and weight-loss therapy Zepbound, with $3.59 billion in sales. The company raised its 2025 guidance, anticipating adjusted profits of $23.00–$23.70 per share. Analysts remain optimistic despite potential challenges from Medicare pricing negotiations.
Oct 30, 2025
Eli Lilly collaborates with Walmart to offer weight loss medication directly to consumers across the country.
Eli Lilly's weight loss drug Zepbound will be available at Walmart pharmacies nationwide through its direct-to-consumer platform, LillyDirect, starting next month. Patients with a valid prescription can access Zepbound for $349 per month, with savings of over 50% compared to similar medications. The drug, approved for chronic weight management, has gained popularity since its FDA approval in 2023.
Oct 30, 2025
Novo Nordisk disrupts Pfizer's Metsera merger with a substantial offer - Rolling Out
Novo Nordisk has launched a $6 billion bid to acquire Metsera, surpassing Pfizer's previous offer of $4.9 billion. This aggressive move aims to secure Metsera's promising obesity treatment, MET-097i. Pfizer has responded with legal threats, claiming Novo's bid is reckless and potentially illegal. The outcome could reshape the competitive landscape in the obesity drug market.
Oct 30, 2025
Pfizer Responds After Novo Nordisk Takes Over Its $8.5 Billion Metsera Agreement - TradingView
Pfizer is outraged after Novo Nordisk made an unexpected $8.5 billion bid for Metsera, a biotech company Pfizer had already agreed to acquire. Novo's offer includes $56.50 per share and $2.5 billion in future milestones. Pfizer criticized the move as reckless and plans to pursue legal action, intensifying competition in the $150 billion obesity drug market.
Oct 29, 2025
F.D.A. Takes Steps to Accelerate the Approval Process for More Affordable Generic Medications - The New York Times
The FDA announced it will ease regulations for biosimilars, low-cost copycat versions of biologic drugs, to reduce drug prices. Notable biosimilars include Herceptin, Lantus, and Humira. The agency will no longer require extensive clinical trials for these drugs and aims to facilitate pharmacists' ability to substitute biosimilars for brand-name prescriptions, promoting competition in the market.
Oct 29, 2025
Discussions on Obesity Medication Pricing: Trump's Negotiations Dwarf Earnings Reports from Lilly and Novo - IndexBox
Investors are closely monitoring price negotiations with President Donald Trump as Eli Lilly and Novo Nordisk prepare to report third-quarter earnings. Lilly's obesity drug Zepbound is expected to perform well, while Novo faces internal challenges. Analysts predict Lilly's sales will rise 40% to $16 billion, while Novo anticipates 8% growth to $12.09 billion.
Oct 29, 2025
GSK has decided to discontinue its CD226 cancer treatment efforts, letting go of the last remaining phase 2 projects.
GSK has abandoned its CD226-related cancer drug programs, including the anti-CD96 antibody nelistotug (GSK6097608) and anti-PVRIG antibody GSK4381562, following setbacks with its anti-TIGIT drug belrestotug. The company also discontinued several infectious disease assets, including the meningitis vaccine GSK4023393. Outgoing CEO Emma Walmsley emphasized the need to refocus on high-potential projects.
Oct 29, 2025
QR Codes on Indian Pharmaceuticals: An Illusion in the Battle Against Counterfeits
India's QR code-based Track & Trace program for pharmaceuticals, launched in late 2022 to protect 300 essential drugs, is struggling against advanced counterfeiting methods, according to experts. The initiative, aimed at combating fake medicines, is facing significant challenges in its implementation.
Oct 29, 2025
FDA takes steps to simplify the approval process for biosimilars while Trump aims to reduce medication expenses.
The Trump administration unveiled a draft framework aimed at expediting the approval of biosimilars, or copycat biologic drugs, to enhance affordability and accessibility for patients. FDA Commissioner Marty Makary stated that the new guidelines will lower clinical standards, reducing development costs and approval times. Final guidance on biosimilars is expected within three to six months.
Oct 29, 2025
PMPRB publishes its Annual Report on Public Drug Plan Spending for 2022/23 - Lexology
On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) released the 10th edition of CompassRx, analyzing prescription drug expenditures in Canadian public drug plans for the 2022/23 fiscal year. The report highlights trends from 2017/18 to 2022/23 and examines cost drivers for drugs and dispensing from 2021/22 to 2022/23.
Oct 28, 2025
Wuxi XDC patent reveals new antibody-drug conjugates | BioWorld
Wuxi XDC (Shanghai) Co. Ltd. and Wuxi XDC Singapore Pvt Ltd. have announced new antibody-drug conjugates that combine antibodies with cytotoxic drugs, showing potential for cancer treatment.
Oct 28, 2025
Eprosartan Mesylate Market Analysis, Key Growth Factors, and Projections for 2035 | Anticipated CAGR of 4.4%
The global eprosartan mesylate market, valued at $200 million in 2024, is projected to grow to $400 million by 2035, driven by rising hypertension prevalence and an aging population. Eprosartan mesylate, an effective angiotensin II receptor blocker, is favored for its tolerability. Key players include Cipla, Aurobindo Pharma, and Teva Pharmaceuticals, amidst increasing competition from generics.
Oct 28, 2025
Teva Pharmaceuticals Agrees to $35 Million Settlement in Antitrust Case Involving Asthma Inhalers
Teva Pharmaceuticals has agreed to a $35 million settlement to resolve an antitrust lawsuit alleging it delayed generic competition for its QVAR asthma inhalers, which contain beclomethasone dipropionate HFA. The settlement includes the withdrawal of six patents from the FDA's Orange Book, potentially allowing for cheaper alternatives. Teva denies wrongdoing, and the agreement awaits judicial approval.
Oct 28, 2025
Novartis Stock Declines While Avidity Biosciences Rises After $12 Billion Acquisition Agreement
Novartis shares fell as Avidity Biosciences surged following a $12 billion acquisition deal. In related news, Innovent Biologics and Eli Lilly's mazdutide outperformed Novo Nordisk's semaglutide in diabetes management. MapLight Therapeutics went public with a $250 million IPO, while Organon’s CEO resigned amid sales practice allegations, reflecting ongoing shifts in the pharmaceutical industry.
Oct 28, 2025
New Acyloin Compound Litchficin Identified in Halophilic Bacteria from Coral Sources
Researchers have discovered a novel acyloin compound named Litchficin from the halophilic bacterium *Litchfieldia sp. TUR-22*, isolated from coral environments. This finding emphasizes the potential of marine microorganisms in producing unique bioactive compounds, with implications for biotechnology and medicine. Further investigations into Litchficin's properties and applications are ongoing.
Oct 28, 2025
Merck's kidney cancer medication shows positive results in two major studies | BioPharma Dive
Merck & Co. has achieved success in two Phase 3 trials for its kidney cancer drug Welireg, showing improved disease-free survival when combined with Keytruda and better progression delay with Lenvima compared to Cabometyx. This could significantly boost Merck's revenue, potentially exceeding $6 billion. Welireg, currently priced at $30,000 per month, may become a key revenue driver post-Keytruda patent expiration.
Oct 28, 2025
Novartis achieves profit goals as new medications compensate for the impact of generics - Yahoo! Finance UK
Novartis reported third-quarter profits meeting forecasts, driven by new drug growth despite a slowdown in sales of its heart drug Entresto, which faces generic competition. The company is pursuing acquisitions, including a $12 billion deal for Avidity, to strengthen its pipeline. CEO Vas Narasimhan stated no expected impact from U.S. trade tariffs on operations.
Oct 28, 2025
Novartis stock declines due to generic competition impacting its top-selling heart medication - Yahoo News Canada
Novartis reported stagnant sales for its heart treatment Entresto, totaling $1.88 billion in Q3, as it faces competition from generics in the U.S. market. The company's shares fell over 3%, highlighting concerns over declining revenue from established drugs. Despite this, Novartis confirmed its 2025 outlook, expecting net sales growth in the "high single-digit" percentage range.
Oct 28, 2025
Novartis reports lower-than-expected earnings due to the impact of losing the Entresto patent. - Halifax – Market news
Novartis reported a 23% rise in net income to $3.93 billion on $13.91 billion in sales, with adjusted earnings per share at $2.25. Despite pressure from generics on Entresto, which generated $1.88 billion, growth was driven by oncology and neurology products like Kisqali and Kesimpta. The company announced a $12 billion acquisition of Avidity Biosciences to enhance its RNA-based therapies.
Oct 28, 2025
Janssen files lawsuit against Juno regarding Invega schizophrenia medication patent | Lawyerly
Janssen Pharmaceutica, a Johnson & Johnson subsidiary, has filed a lawsuit against Juno Pharmaceuticals, claiming that Juno's efforts to list its own schizophrenia drug on the PBS infringe on Janssen's patent for Invega.
Oct 28, 2025
Novartis stock declines due to generic competition impacting major heart medication - Yahoo Finance
Novartis' heart treatment Entresto experienced stagnant sales of $1.88 billion in Q3, impacted by generic competition following its patent expiration. The company's shares fell over 3%, despite a solid earnings report. CEO Vas Narasimhan confirmed no expected impact from U.S. trade tariffs and reiterated the 2025 outlook, projecting net sales growth in the high single digits.
Oct 28, 2025
Novartis reports lower-than-expected earnings due to the impact of Entresto patent expiration - Sharecast.com
Novartis shares fell 3.37% after the company reported a 23% rise in net income to $3.93 billion and 7% sales growth to $13.91 billion, but missed earnings expectations due to patent loss on its heart drug Entresto. The company announced a $12 billion acquisition of Avidity Biosciences to enhance its RNA-based therapies amid ongoing competition from generics.
Oct 28, 2025
Incyte abandons its BET inhibitor and anti-CD122 medication - Fierce Biotech
Incyte has halted development of its BET inhibitor INCB57643 due to ongoing pipeline prioritization, not safety concerns. The drug was being evaluated in a phase 2 myelofibrosis study alongside Jakafi. Incyte is also discontinuing work on anti-CD122 drug INCA034460 and povorcitinib for chronic spontaneous urticaria, while planning submissions for hidradenitis suppurativa approval.
Oct 28, 2025
Rocket Science Health Receives U.S. Patent for Innovative Fluid Dynamics Technique in Targeted Drug Delivery
Rocket Science Health Corp. has been granted U.S. Patent No. 12,403,275 for its innovative fluid dynamics methodology that enhances precision in intranasal drug delivery. This technology allows for targeted delivery to specific nasal cavity regions, improving access to the central nervous system. The patent strengthens Rocket Science's intellectual property portfolio, supporting advancements in therapies for mental health and neurodegenerative disorders.
Oct 28, 2025
Trends and Global Insights in the Anti-Aging Pharmaceuticals Market - GlobeNewswire
The anti-aging drugs market is projected to grow from USD 79 million in 2025 to USD 2.80 billion by 2040, with a CAGR of 27%. Over 65 therapeutics are in development, primarily by small firms in North America. Key players include AgelessRx, BioAge Labs, and Mayo Clinic. The market is expected to be dominated by Europe and Asia Pacific, capturing over 75% of the share.
Oct 28, 2025
Pharma 4.0: The Impact of AI on the Future of the Pharmaceutical Industry - TNGlobal
The pharmaceutical industry faces a significant revenue decline due to a patent cliff, with over $200 billion projected to vanish as blockbuster drugs lose patent protection. Companies like Genentech and Sanofi are accelerating transformation through AI integration in R&D. Startups like Therapi AI are also innovating with active AI agents, marking a shift towards Pharma 4.0 and redefining industry competition.
Oct 28, 2025
Is It a Good Idea to Invest in AbbVie Stock Before the Q3 Earnings Announcement? - TradingView
AbbVie (ABBV) is set to report its Q3 2025 earnings on October 31, with sales estimated at $15.59 billion and earnings at $1.80 per share. Despite a strong performance from immunology drugs Skyrizi and Rinvoq, AbbVie faces challenges from Humira's patent loss and high IPR&D expenses. Short-term investors may consider selling, while long-term investors may remain optimistic.
Oct 28, 2025
The rate of obesity is declining as more Americans opt for weight-loss medications - PhillyVoice
A new Gallup report reveals that obesity rates in the U.S. have decreased from nearly 40% in 2022 to 37% in 2025, coinciding with increased use of GLP-1 weight-loss drugs like Ozempic and Wegovy. However, diabetes rates have risen to 13.8%, highlighting the complexity of the relationship between obesity and diabetes.
Oct 28, 2025
GSK Expands Its Respiratory Portfolio with a New Early-Stage Treatment for COPD Utilizing an Innovative Method
GSK has acquired rights to Empirico's early-stage COPD drug candidate, EMP-012, for $85 million. This siRNA therapy targets a distinct inflammatory pathway and could enhance GSK's respiratory portfolio, which includes the blockbuster Nucala and Trelegy Ellipta. The deal allows GSK to develop and commercialize EMP-012, with potential milestone payments totaling $660 million for Empirico.
Oct 28, 2025
India intensifies investigation into anti-dumping measures concerning 'Ethambutol Hydrochloride' imports from China and Thailand.
India has initiated an anti-dumping investigation into imports of Ethambutol Hydrochloride from China and Thailand, a key ingredient in anti-tuberculosis medications. The move follows the release of a list of registered interested parties as part of the probe.
Oct 27, 2025
Novartis Invests $12 Billion in Ambitious Biotech Venture—Key Insights for Investors
Novartis (NVS) has agreed to acquire Avidity Biosciences for $12 billion in cash, paying $72 per share, a 46% premium. This strategic move aims to enhance Novartis' focus on RNA-based medicines for genetic diseases. The deal, expected to close in 2026, could boost Novartis' sales growth rate and marks a significant shift towards innovative biotech platforms.
Oct 27, 2025
Novartis to Purchase Avidity Biosciences for $12 Billion - Estoy en la Frontera
Novartis AG has agreed to acquire Avidity Biosciences, Inc. for approximately $12 billion in cash, offering Avidity shareholders $72 per share. This acquisition aims to enhance Novartis's portfolio in rare neuromuscular disorders. Avidity will spin off its cardiology programs into a new entity, SpinCo, led by Kathleen Gallagher. The deal is expected to close in the first half of 2026.
Oct 27, 2025
Laxxon Medical Set to Participate in BIO-Europe and Jefferies Healthcare Conference World Premiere
Laxxon Medical, a leader in pharmaceutical technology, will attend BIO-Europe 2025 and the Jefferies Healthcare Conference to showcase its SPID®-Technology, an innovative oral drug delivery system. CEO Helmut Kerschbaumer emphasized the potential for new collaborations to enhance drug development. The company’s pipeline includes partnerships with major pharma and biotech firms, supported by over 230 patents.
Oct 27, 2025
BioRestorative Receives Notice of Allowance for Patent in Japan - GlobeNewswire
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a significant milestone with the Japanese Patent Office granting a Notice of Allowance for its ThermoStem® platform, which utilizes brown adipose-derived stem cells (BADSC) to address obesity and metabolic disorders. This patent strengthens BRTX's position against GLP-1 drugs, offering potential advantages in safety and efficacy.
Oct 27, 2025
PvPI detects 16 signals specific to India and issues 183 alerts regarding drug safety to enhance patient safety.
The Pharmacovigilance Programme of India (PvPI) has identified 16 India-specific signals and 183 drug safety alerts aimed at enhancing patient safety. These findings have been communicated to the Central Drugs Standard Control Organisation (CDSCO) for necessary regulatory actions.
Oct 27, 2025
Eli Lilly's Stock Drops 15%: Is It Time to Invest? - Yahoo Finance
Eli Lilly (NYSE: LLY), a leading pharmaceutical company with a market cap of $730 billion, is well-positioned in the weight loss drug market, particularly with its GLP-1 drugs Mounjaro and Zepbound. However, its stock is currently 15% below its 2024 high, and analysts caution against buying due to its low dividend yield of 0.7%, indicating potential overvaluation.
Oct 27, 2025
The influence of patent activity on unique volatility in American pharmaceutical firms.
A recent study published in PLoS One analyzes the impact of patent activity on idiosyncratic volatility (IVOL) in U.S. pharmaceutical companies from 2005 to 2024. Findings indicate that while patents generally reduce IVOL, early-stage development projects initially increase risk. Successful commercialization significantly mitigates volatility, highlighting the complex relationship between innovation and firm-specific risk in the pharmaceutical sector.
Oct 27, 2025
Teva Reaches Agreement Over Allegations of Hindering Affordable QVAR Alternatives - PYMNTS.com
Teva Pharmaceuticals has agreed to pay $35 million and remove six patents related to its QVAR asthma inhalers to settle claims of delaying generic competition. The settlement, pending judicial approval, addresses allegations from consumers and payors that Teva's actions inflated prices. The case, filed in 2023, is titled Iron Workers District Council of New England Health and Welfare Fund et al v. Teva Pharmaceutical Industries Ltd.
Oct 27, 2025
3 Discounted Pharmaceutical Stocks Offering Dividends to Consider Purchasing
Major pharmaceutical companies Pfizer, Bristol Myers Squibb, and Merck are currently trading at attractive valuations, with yields of 7%, 5.6%, and 3.7%, respectively. Pfizer's high yield comes with risks, including a 90% payout ratio and a recent $4.9 billion acquisition of Metsera. Bristol Myers Squibb faces a 99% payout ratio but has a strong acquisition strategy. Merck offers a more stable profile with a 50% payout ratio.
Oct 27, 2025
BioRestorative Receives Notice of Allowance for Japanese Patent – Enhances Protection for ...
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a significant milestone with the Japanese Patent Office granting a Notice of Allowance for its ThermoStem® platform, which utilizes brown adipose-derived stem cells (BADSC) to address obesity and metabolic disorders. This patent strengthens BRTX's position against GLP-1 drugs, offering potential advantages in safety and efficacy.
Oct 27, 2025
How Eli Lilly's Mounjaro Outpaced Novo Nordisk's Wegovy in India's Weight-Loss Market
Eli Lilly's Mounjaro (tirzepatide) has emerged as the leading weight-loss drug in India, achieving monthly sales of Rs 80 crore since its March 2025 launch, significantly outpacing Novo Nordisk's Wegovy (semaglutide), which reported Rs 9 crore. Mounjaro's dual-action mechanism offers greater weight loss, while both drugs remain costly. Lilly is also partnering with Cipla to expand distribution.
Oct 27, 2025
JNJ vs. MRK: Which Leading Pharmaceutical Stock Belongs in Your Investment Portfolio? - TradingView
Johnson & Johnson (JNJ) and Merck (MRK) are compared as leading U.S. healthcare companies. JNJ shows steady growth in its diversified portfolio, particularly in oncology and MedTech, while Merck relies heavily on Keytruda, facing challenges from patent expirations and competition. Analysts favor JNJ for its stronger financial position and growth prospects, despite headwinds like the Stelara patent cliff and talc lawsuits.
Oct 27, 2025
What Can We Expect from These 5 Major Pharmaceutical Companies This Earnings Season? - TradingView
The Medical sector's third-quarter earnings season is underway, with major firms like Johnson & Johnson, Roche, Eli Lilly, Merck, AbbVie, Bristol Myers, and Gilead Sciences set to report results. Johnson & Johnson raised its 2025 sales expectations, while Roche anticipates higher earnings growth. Eli Lilly's performance is driven by GLP-1 drugs, and Merck's growth is attributed to Keytruda sales.
Oct 27, 2025
Which Pharmaceutical Stock Is Considered a Top Buy at This Time? - The Globe and Mail
Pfizer has acquired Metsera for $4.9 billion, entering the growing anti-obesity drug market dominated by GLP-1 medications like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Metsera's candidate, MET-233i, shows promise with significant weight loss results. The anti-obesity drug market is projected to reach $100 billion in five years, highlighting the potential for Pfizer's investment.
Oct 27, 2025
What Can We Expect from These 5 Major Pharmaceutical Companies This Earnings Season? - The Globe and Mail
The Medical sector's third-quarter earnings season is underway, with major firms like Johnson & Johnson, Roche, Eli Lilly, Merck, AbbVie, Bristol Myers, and Gilead Sciences set to report results. Roche anticipates higher earnings due to strong demand for drugs like Phesgo and Keytruda. Eli Lilly's performance is bolstered by GLP-1 drugs, while Gilead's HIV therapies remain key revenue drivers.
Oct 27, 2025
Insights for the Biopharmaceutical Industry from the Entresto® Case | Fish & Richardson - JD Supra
After over six years of litigation, generic versions of Novartis Pharmaceuticals' Entresto® (sacubitril/valsartan) have launched. The legal battle involved patent infringement claims, particularly around U.S. Patent No. 8,101,659, and regulatory challenges with the FDA. Despite Novartis' efforts to protect its blockbuster drug, multiple generics entered the market following the expiration of pediatric exclusivity.
Oct 26, 2025
Novartis set to purchase Avidity Biosciences for approximately $12 billion.
Swiss drugmaker Novartis has agreed to acquire U.S. biotech firm Avidity Biosciences for approximately $12 billion to enhance its portfolio in rare muscle disorder treatments. Avidity's lead drug, Del-zota, targets Duchenne muscular dystrophy. The acquisition aligns with Novartis' strategy to strengthen its U.S. presence amid potential tariffs and follows other significant deals in the sector.
Oct 26, 2025
Telangana DCA emphasizes the importance of keeping accurate prescription records to prevent steroid abuse.
The Telangana Drugs Control Administration (DCA) has mandated pharmacies to maintain accurate prescription records for anabolic-androgenic steroids and cardiac stimulants. This initiative aims to prevent the misuse of these substances for bodybuilding and other non-medical purposes.
